| ［1］ |
Siegel RL， Miller KD， Fuchs HE， et al. Cancer statistics， 2021［J］.CA Cancer J Clin， 2021， 71（1）：7-33.
|
| ［2］ |
Bray F， Laversanne M， Sung H， et al. Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2024， 74（3）： 229-263.
|
| ［3］ |
Pang JM， Gorringe KL， Fox SB. Ductal carcinoma in situ - update on risk assessment and management［J］. Histopathology， 2016， 68（1）：96-109.
|
| ［4］ |
Lagios MD，Silverstein MJ. Ductal carcinoma in situ：recent history and areas of controversy［J］. Breast J， 2015， 21（1）：21-26.
|
| ［5］ |
Ryser MD， Weaver DL， Zhao F， et al. Cancer outcomes in DCIS patients without locoregional treatment［J］. J Natl Cancer Inst， 2019，111（9）：952-960.
|
| ［6］ |
Casasent AK， Edgerton M， Navin NE. Genome evolution in ductal carcinoma in situ：invasion of the clones［J］. J Pathol，2017，241（2）：208-218.
|
| ［7］ |
Casasent AK， Schalck A， Gao R， et al. Multiclonal invasion in breast tumors identified by topographic single cell sequencing［J］. Cell，2018，172（1-2）：205-217.e12.
|
| ［8］ |
Petridis C， Brook MN， Shah V， et al. Genetic predisposition to ductal carcinoma in situ of the breast［J］. Breast Cancer Res，2016，18（1）：22.
|
| ［9］ |
Wong H， Lau S， Yau T， et al. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer［J］. Br J Cancer， 2010， 102（9）：1391-1396.
|
| ［10］ |
Ruszczyk M， Zirpoli G， Kumar S， et al. Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses［J］. Cancer Causes Control， 2016， 27（2）：183-198.
|
| ［11］ |
Doebar SC， Sieuwerts AM， de Weerd V， et al. Gene expression differences between ductal carcinoma in situ with and without progression to invasive breast cancer［J］. Am J Pathol，2017，187（7）：1648-1655.
|
| ［12］ |
Liu Y，Pandey PR，Sharma S，et al. ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness［J］. Breast Cancer Res Treat， 2019， 175（1）：77-90.
|
| ［13］ |
Song G，He L，Yang X，et al. Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma［J］. J Int Med Res， 2020， 48（1）：300060518815364.
|
| ［14］ |
Lin CY， Vennam S， Purington N， et al. Genomic landscape of ductal carcinoma in situ and association with progression［J］. Breast Cancer Res Treat， 2019， 178（2）：307-316.
|
| ［15］ |
Johnson KC， Koestler DC， Fleischer T， et al. DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer［J］. Clin Epigenetics， 2015， 7（1）：75.
|
| ［16］ |
DeVaux RS， Herschkowitz JI. Beyond DNA： the role of epigenetics in the premalignant progression of breast cancer［J］. J Mammary Gland Biol Neoplasia， 2018， 23（4）：223-235.
|
| ［17］ |
Hannafon BN， Ding WQ. miRNAs as biomarkers for predicting the progression of ductal carcinoma in situ ［J］. Am J Pathol， 2018，188（3）：542-549.
|
| ［18］ |
Bu L， Baba H， Yoshida N， et al. Biological heterogeneity and versatility ofcancer-associatedfibroblastsinthetumor microenvironment［J］. Oncogene， 2019， 38（25）：4887-4901.
|
| ［19］ |
Dawoud MM， Jones DT， Chelala C， et al. Expression profile of myoepithelial cells in DCIS： do they change from protective angels to wicked witches？ ［J］. Appl Immunohistochem Mol Morphol， 2022，30（6）：397-409.
|
| ［20］ |
Yeong J， Thike AA， Tan PH， et al. Identifying progression predictors of breast ductal carcinoma in situ［J］. J Clin Pathol， 2017， 70（2）：102-108.
|
| ［21］ |
Chen XY， Yeong J， Thike AA， et al. Prognostic role of immune infiltrates in breast ductal carcinoma in situ［J］. Breast Cancer Res Treat， 2019， 177（1）：17-27.
|
| ［22］ |
Kim M， Chung YR， Kim HJ， et al. Immune microenvironment in ductal carcinoma in situ： a comparison with invasive carcinoma of the breast［J］. Breast Cancer Res， 2020， 22（1）：32.
|
| ［23］ |
Gil Del Alcazar CR， Aleˇckovic′ M， Polyak K. Immune escape during breast tumor progression［J］. Cancer Immunol Res， 2020， 8（4）：422-427.
|
| ［24］ |
Niwińska A，Olszewski WP. The role of stromal immune microenvironment in the progression of ductal carcinoma in situ （DCIS） to invasive breast cancer［J］. Breast Cancer Res， 2021， 23（1）：118.
|
| ［25］ |
Yu LN，Liu Z，Tian Y，et al. FAP-a and GOLPH3 are hallmarks of DCIS progression to invasive breast cancer［J］. Front Oncol， 2019， 9：1424.
|
| ［26］ |
Elsarraj HS， Hong Y， Limback D， et al. BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression［J］. NPJ Breast Cancer， 2020， 6：12.
|
| ［27］ |
Kim M， Choi HY， Woo JW， et al. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast［J］. Sci Rep， 2021，11（1）：18007.
|
| ［28］ |
Lopez Gordo S， Blanch Falp J， Lopez-Gordo E， et al. Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study［J］. Int J Surg， 2019， 63：98-106.
|
| ［29］ |
Goh CW， Wu J， Ding S， et al. Invasive ductal carcinoma with coexisting ductal carcinoma in situ （IDC/DCIS） versus pure invasive ductal carcinoma （ IDC）： a comparison of clinicopathological characteristics， molecular subtypes， and clinical outcomes ［J］. J Cancer Res Clin Oncol， 2019， 145（7）：1877-1886.
|
| ［30］ |
Kole AJ， Park HS， Johnson SB， et al. Overall survival is improved when DCIS accompanies invasive breast cancer［J］. Sci Rep， 2019，9（1）：9934.
|
| ［31］ |
Chen H， Bai F， Wang M， et al. The prognostic significance of coexistence ductal carcinoma in situ in invasive ductal breast cancer： a large population-based study and a matched case-control analysis［J］.Ann Transl Med， 2019， 7（18）：484.
|
| ［32］ |
Dieterich M， Hartwig F，Stubert J，et al. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival［J］. Breast， 2014， 23（4）：346-351.
|
| ［33］ |
Wong H， Lau S， Leung R， et al. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer［J］. Med Oncol， 2012， 29（3）：1536-1542.
|
| ［34］ |
Guan X， Xu G， Shi A， et al. Comparison of clinicopathological characteristics and prognosis among patients with pure invasive ductal carcinoma， invasive ductal carcinoma coexisted with invasive micropapillary carcinoma， and invasive ductal carcinoma coexisted with ductal carcinoma in situ： a retrospective cohort study［J］. Medicine（Baltimore）， 2020， 99（50）：e23487.
|
| ［35］ |
Carabias-Meseguer P， Zapardiel I， Cusidó-Gimferrer M， et al.Influence of the in situ component in 389 infiltrating ductal breast carcinomas［J］. Breast Cancer， 2013， 20（3）：213-217.
|
| ［36］ |
Zeng Y， Gao W，Chen X，et al. Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component［J］. Br J Cancer， 2021， 124（5）：975-981.
|